<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04810910</url>
  </required_header>
  <id_info>
    <org_study_id>INEO-P-005</org_study_id>
    <nct_id>NCT04810910</nct_id>
  </id_info>
  <brief_title>Personalized Neoantigen Vaccine in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy</brief_title>
  <official_title>Clinical Study of a Personalized Neoantigen Vaccine in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhejiang Provincial People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hangzhou Neoantigen Therapeutics Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Zhejiang Provincial People's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research study is evaluating a new type of pancreatic cancer vaccine called&#xD;
      &quot;Personalized Neoantigen Cancer Vaccine&quot; as a possible treatment for pancreatic cancer&#xD;
      patients following surgical resection and adjuvant chemotherapy. The purpose of the clinical&#xD;
      study is evaluating the safety, tolerability and partial efficacy of the personalized&#xD;
      neoantigen cancer vaccine in the treatment of resectable pancreatic cancer, so as to provide&#xD;
      a new personalized therapeutic strategy.&#xD;
&#xD;
      It is known that cancer patients have mutations (changes in genetic material) that are&#xD;
      specific to an individual patient and tumor. These mutations can cause the tumor cells to&#xD;
      produce proteins that appear very different from the body's own cells. It is possible that&#xD;
      these proteins used in a vaccine may induce strong immune responses, which may help the&#xD;
      participant's body fight any tumor cells that could cause the cancer to come back in the&#xD;
      future. The study will examine the safety of the vaccine when given at several different time&#xD;
      points and will examine the participant's blood cells for signs that the vaccine induced an&#xD;
      immune response.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 30, 2021</start_date>
  <completion_date type="Anticipated">March 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">March 30, 2025</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants experiencing clinical and laboratory adverse events (AEs)</measure>
    <time_frame>1 years</time_frame>
    <description>Adverse events will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events v5.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Relapse Free Survival(RFS)</measure>
    <time_frame>4 years</time_frame>
    <description>Time from surgery to any recurrence</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival(OS)</measure>
    <time_frame>4 years</time_frame>
    <description>Time from surgery to death or last follow-up</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Measurement of CD4/CD8 T lymphocyte subsets</measure>
    <time_frame>2 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>The polypeptide antigen - induced IFN-γ T cells responses</measure>
    <time_frame>2 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Peripheral blood T cell receptor sequencing analysis</measure>
    <time_frame>2 years</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Resectable Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Personalized neoantigen vaccines</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>iNeo-Vac-P01 (peptides)： 4 x 300 mcg per peptide given on days 1, 4, 8, 15, 22, 52, and 82 for a total of 7 doses;&#xD;
GM-CSF: 4 x 40 mcg (total dose 160 mcg) given on days 1, 4, 8, 15, 22, 52, and 82 for a total of 7 doses</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>iNeo-Vac-P01</intervention_name>
    <description>iNeo-Vac-P01 (peptides)： 300 mcg per peptide</description>
    <arm_group_label>Personalized neoantigen vaccines</arm_group_label>
    <other_name>Neoantigen peptides</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>GM-CSF</intervention_name>
    <description>GM-CSF: 40 mcg</description>
    <arm_group_label>Personalized neoantigen vaccines</arm_group_label>
    <other_name>immune adjuvant</other_name>
    <other_name>granulocyte-macrophage colony stimulating factor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria：&#xD;
&#xD;
          1. Must freely sign informed consent;&#xD;
&#xD;
          2. Aged 18 to 70 years old;&#xD;
&#xD;
          3. Histologically or cytologically confirmed diagnosis of pancreatic adenocarcinoma;&#xD;
&#xD;
          4. Must provide all exons of tumor tissue sequencing data, transcriptome sequencing data&#xD;
             and the peripheral blood of all exons sequencing data;&#xD;
&#xD;
          5. ECOG score is 0 or 1;&#xD;
&#xD;
          6. Completed an R0 or R1 surgical resection as determined by pathology；&#xD;
&#xD;
          7. Completion of at least 4 months of adjuvant chemotherapy with ticgio monotherapy or&#xD;
             mFOLFIRINOX;&#xD;
&#xD;
          8. Completion of imaging records 1 week before personalized immunotherapy, including but&#xD;
             not limited to full-body PET-CT and brain MRI,&#xD;
&#xD;
          9. The end of chemotherapy is followed by a one-week natural washout period；&#xD;
&#xD;
         10. Haematological index：&#xD;
&#xD;
               -  White blood cells ≥ 3500 / MCL&#xD;
&#xD;
               -  Lymphocytes &gt; 800/ MCL&#xD;
&#xD;
               -  neutrophils &gt; 1500/ MCL&#xD;
&#xD;
               -  Platelets &gt; 100000 / MCL&#xD;
&#xD;
               -  Hemoglobin &gt;10.0g/dL&#xD;
&#xD;
               -  Total serum bilirubin &lt;1.5× upper limit of normal value (ULN)&#xD;
&#xD;
               -  AST/ALT&lt;2.0 times the upper limit of normal&#xD;
&#xD;
               -  Serum creatinine &lt;1.5 times the upper limit of normal；&#xD;
&#xD;
         11. Pregnant, lactating women and women of child-bearing age must have a negative&#xD;
             pregnancy test within 7 days before entering the group, and short-term have no&#xD;
             fertility plan, and are willing to take protective measures (contraception or other&#xD;
             birth control methods) before and during the clinical trial;&#xD;
&#xD;
         12. Good compliance, able to follow research protocols and follow-up procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Evidence of disease recurrence or metastasis following surgical resection at any time&#xD;
             prior to the first vaccination administration.&#xD;
&#xD;
          2. Diagnosed as other malignant tumor;&#xD;
&#xD;
          3. No neoantigen was found in the sequencing data;&#xD;
&#xD;
          4. There have been bone marrow or stem cell transplants;&#xD;
&#xD;
          5. Received systemic glucocorticoids with immunosuppressants;&#xD;
&#xD;
          6. Received other polypeptide inoculation 4 weeks before treatment; Patients may not be&#xD;
             vaccinated with other polypeptides 8 weeks after the last individualized tumor&#xD;
             targeted polypeptides trentment;&#xD;
&#xD;
          7. With HIV, HCV, HBV infection, severe asthma, autoimmune disease, immunodeficiency or&#xD;
             treated with immunosuppressive drugs;&#xD;
&#xD;
          8. Uncontrolled complications include, but are not limited to, active infection,&#xD;
             symptomatic congestive heart failure, unstable angina pectoris, and arrhythmias;&#xD;
&#xD;
          9. Infected with herpes virus (except those with scabs of more than 4 weeks)；&#xD;
&#xD;
         10. Infected with respiratory virus (except those who have recovered for more than 4&#xD;
             weeks);&#xD;
&#xD;
         11. Have severe coronary or cerebrovascular disease, or other conditions considered&#xD;
             ineligible by the investigator;&#xD;
&#xD;
         12. Drug abuse. Clinical, psychological or social factor result in affecting informed&#xD;
             consent or research implementation;&#xD;
&#xD;
         13. Have a history of drug or polypeptide allergies, or people who are allergic to other&#xD;
             potential immunotherapies.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yang Liu, Liu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zhejiang Provincial People's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yang Liu, M.D.</last_name>
    <phone>13666601475</phone>
    <email>yangliuqq2003@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Zhejiang Provincial People's Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yang Liu, M.D.</last_name>
      <phone>13666601475</phone>
      <email>yangliuqq2003@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>March 19, 2021</study_first_submitted>
  <study_first_submitted_qc>March 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 23, 2021</study_first_posted>
  <last_update_submitted>November 15, 2021</last_update_submitted>
  <last_update_submitted_qc>November 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Zhejiang Provincial People's Hospital</investigator_affiliation>
    <investigator_full_name>Liu Yang</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Molgramostim</mesh_term>
    <mesh_term>Sargramostim</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

